Global Beer Yeast Processing Equipment Market Growth 2025-2031
Description
The global NK1 Receptor Antagonist market size is predicted to grow from US$ 744 million in 2025 to US$ 1051 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
NK1 receptor antagonists (Neurokinin-1 receptor antagonists) are a class of medications that prevent and control chemotherapy-induced nausea and vomiting (CINV) by blocking the binding of substance P to the NK1 receptors in the central nervous system. These agents are typically used in combination with 5-HT3 receptor antagonists and corticosteroids to effectively manage both acute and delayed phases of CINV, and they are considered standard supportive care in moderate to highly emetogenic chemotherapy regimens.
United States market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key NK1 Receptor Antagonist players cover Merck, Helsinn Healthcare, TerSera Therapeutics, Heron Therapeutics, Glenmark, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “NK1 Receptor Antagonist Industry Forecast” looks at past sales and reviews total world NK1 Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected NK1 Receptor Antagonist sales for 2025 through 2031. With NK1 Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NK1 Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global NK1 Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK1 Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NK1 Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK1 Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK1 Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of NK1 Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Aprepitant
Rolapitant
Fosaprepitant
Netupitant
Maropitant
Other
Segmentation by Application:
Hospital
Specialty Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Helsinn Healthcare
TerSera Therapeutics
Heron Therapeutics
Glenmark
Torrent Pharmaceuticals
Fresenius Kabi
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Beijing Sihuan Pharmaceutical
Yichang Humanwell Pharmaceutical
Hansoh Pharma
Luoxin Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global NK1 Receptor Antagonist market?
What factors are driving NK1 Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NK1 Receptor Antagonist market opportunities vary by end market size?
How does NK1 Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
NK1 receptor antagonists (Neurokinin-1 receptor antagonists) are a class of medications that prevent and control chemotherapy-induced nausea and vomiting (CINV) by blocking the binding of substance P to the NK1 receptors in the central nervous system. These agents are typically used in combination with 5-HT3 receptor antagonists and corticosteroids to effectively manage both acute and delayed phases of CINV, and they are considered standard supportive care in moderate to highly emetogenic chemotherapy regimens.
United States market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for NK1 Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key NK1 Receptor Antagonist players cover Merck, Helsinn Healthcare, TerSera Therapeutics, Heron Therapeutics, Glenmark, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “NK1 Receptor Antagonist Industry Forecast” looks at past sales and reviews total world NK1 Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected NK1 Receptor Antagonist sales for 2025 through 2031. With NK1 Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NK1 Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global NK1 Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK1 Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NK1 Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK1 Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK1 Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of NK1 Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Aprepitant
Rolapitant
Fosaprepitant
Netupitant
Maropitant
Other
Segmentation by Application:
Hospital
Specialty Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Helsinn Healthcare
TerSera Therapeutics
Heron Therapeutics
Glenmark
Torrent Pharmaceuticals
Fresenius Kabi
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Beijing Sihuan Pharmaceutical
Yichang Humanwell Pharmaceutical
Hansoh Pharma
Luoxin Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global NK1 Receptor Antagonist market?
What factors are driving NK1 Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NK1 Receptor Antagonist market opportunities vary by end market size?
How does NK1 Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
115 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Beer Yeast Processing Equipment by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Beer Yeast Processing Equipment by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
